Xavier Montalban, MD, PhD - Multiple Sclerosis and Bruton’s Tyrosine Kinase Inhibitors: Therapeutic Potential Beyond Biologics‪?‬ PeerVoice Immunology & Infectious Disease Video

Visit https://www.peervoice.com/BBT860 to view the entire programme with slides. After completing “Xavier Montalban, MD, PhD - Multiple Sclerosis and Bruton’s Tyrosine Kinase Inhibitors: Therapeutic Potential Beyond Biologics?”, participants will be able to: Describe the benefits and limitations of current disease-modifying strategies in multiple sclerosis (MS); Discuss the role of Bruton’s tyrosine kinase (BTK) in the pathological processes associated with disease progression in patients with MS; and Use clinical data to evaluate on-target and off-target effects of emerging BTK inhibitors for patients with MS in the context of current clinical management.